How should a temperature‑related allergy (cold‑induced urticaria) be managed?

Management of Cold-Induced Urticaria

Initiate high-dose, non-sedating second-generation H1-antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) as first-line therapy, and prescribe an epinephrine auto-injector given the substantial 21% risk of anaphylaxis. 1, 2

Diagnostic Confirmation

• Perform an ice cube test (cold stimulation testing) to confirm the diagnosis—wheals typically develop during rewarming after cold exposure 3, 4
• Look specifically for wheals or angioedema that appear within minutes of cold exposure (drinking cold beverages, swimming, cold air) and resolve within an hour 4, 5
• Distinguish between typical cold urticaria (immediate response to cold) and atypical forms (delayed or systemic presentations) through the pattern and timing of symptoms 3
• Search for underlying infections or systemic conditions only if the patient's history suggests secondary causes; routine extensive workup is not indicated for idiopathic cases 4, 6

Stepwise Treatment Algorithm

Step 1: Antihistamine Therapy

• Start with standard-dose second-generation H1-antihistamines once daily 1, 2
• Offer at least two different antihistamine options since individual response varies significantly 1
• If standard dosing provides insufficient control, up-dose up to four-fold the standard dose 1, 7
• Approximately 96% of cold urticaria patients are managed with antihistamines as primary therapy 2

Step 2: Omalizumab for Refractory Cases

• Add omalizumab 300 mg subcutaneously every 4 weeks for patients who fail high-dose antihistamines 1
• Allow up to 6 months to assess therapeutic response 1
• If response remains inadequate, increase to 600 mg every 14 days 1
• Note that only about 6% of cold urticaria patients currently receive omalizumab, though it is guideline-recommended for antihistamine-refractory disease 2

Step 3: Cyclosporine

• Reserve cyclosporine for patients unresponsive to both antihistamines and omalizumab 1
• Monitor blood pressure and renal function closely due to risks of hypertension and renal impairment 1

Anaphylaxis Risk Management

The risk of cold-induced anaphylaxis is 21%, making epinephrine auto-injector prescription essential 2. This contradicts the general urticaria guideline that states epinephrine is not indicated for simple urticaria with fever 1, but cold urticaria carries unique anaphylaxis risk.

• Prescribe epinephrine auto-injectors to all patients with cold urticaria given the substantial anaphylaxis prevalence 2, 6
• Educate patients that anaphylaxis can occur with whole-body cold exposure (swimming in cold water, cold weather) 8, 5
• Elevated absolute eosinophil count may predict higher anaphylaxis risk 8
• Instruct immediate epinephrine use for systemic symptoms (difficulty breathing, vomiting, abdominal pain, hypotension) following cold exposure 6, 5

Critical Avoidance Measures

• Cold avoidance is fundamental: counsel patients to avoid swimming in cold water, drinking ice-cold beverages, and prolonged cold weather exposure 4, 6
• Avoid NSAIDs and aspirin as they can exacerbate urticaria 1
• Use ACE inhibitors with caution when angioedema is present 1

Special Pediatric Considerations

• Cold urticaria in children has a lower resolution rate compared to chronic spontaneous urticaria (4.8 per 100 patient-years) 8
• Concomitant chronic spontaneous urticaria predicts poorer disease control on standard antihistamines 8
• The median age of symptom onset in children is 9.5 years 8
• Consider familial cryopyrin-associated periodic syndrome in atypical presentations, which may require IL-1 blockade 6

Common Pitfalls

• Do not dismiss cold urticaria as benign—the 21% anaphylaxis risk demands aggressive preventive measures 2
• Do not perform extensive laboratory workup (complement levels, autoimmune panels) unless history suggests secondary disease 4
• Do not withhold epinephrine auto-injectors based on general urticaria guidelines; cold urticaria is a distinct high-risk subtype 2, 6
• Recognize that patients with pre-existing chronic spontaneous urticaria can develop comorbid cold urticaria, requiring reassessment if new anaphylaxis occurs 5